World Journal of Hepatology最新文献

{"title":"Smartphone-based Stroop Test, EncephalApp: What is the optimal cutoff for diagnosing minimal hepatic encephalopathy?","authors":"Ryota Masuzaki, Hirofumi Kogure","doi":"10.4254/wjh.v17.i3.101649","DOIUrl":"10.4254/wjh.v17.i3.101649","url":null,"abstract":"<p><p>Jiang <i>et al</i> explored the diagnostic capabilities of EncephalApp, a smartphone-based Stroop Test, in patients with nonalcoholic liver disease. The study included 160 patients with nonalcoholic cirrhosis and utilized the psychometric hepatic encephalopathy score as a benchmark for diagnosing minimal encephalopathy. The identified optimal cutoff times were > 101.93 seconds for the \"off\" time and > 205.86 seconds for the combined \"on + off\" time, demonstrating sensitivities of 0.84 and 0.90, and specificities of 0.77 and 0.71, respectively. The findings suggest the necessity of employing different cutoffs for patients with alcoholic <i>vs</i> nonalcoholic liver cirrhosis, reflecting the distinct pathophysiologies underlying each condition. Additionally, alcohol consumption itself may influence Stroop test outcomes. Therefore, it is reasonable to establish separate benchmarks for alcoholic and nonalcoholic cirrhotic patients. Further validation in larger patient cohorts with clinical outcomes is essential. The demand for noninvasive liver disease assessments remains high in clinical practice.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"101649"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global trends in artificial intelligence applications in liver disease over seventeen years.","authors":"Xue-Qin Zhou, Shu Huang, Xia-Min Shi, Sha Liu, Wei Zhang, Lei Shi, Mu-Han Lv, Xiao-Wei Tang","doi":"10.4254/wjh.v17.i3.101721","DOIUrl":"10.4254/wjh.v17.i3.101721","url":null,"abstract":"<p><strong>Background: </strong>In recent years, the utilization of artificial intelligence (AI) technology has gained prominence in the field of liver disease.</p><p><strong>Aim: </strong>To analyzes AI research in the field of liver disease, summarizes the current research status and identifies hot spots.</p><p><strong>Methods: </strong>We searched the Web of Science Core Collection database for all articles and reviews on hepatopathy and AI. The time spans from January 2007 to August 2023. We included 4051 studies for further collection of information, including authors, countries, institutions, publication years, keywords and references. VOS viewer, CiteSpace, R 4.3.1 and Scimago Graphica were used to visualize the results.</p><p><strong>Results: </strong>A total of 4051 articles were analyzed. China was the leading contributor, with 1568 publications, while the United States had the most international collaborations. The most productive institutions and journals were the <i>Chinese Academy of Sciences</i> and <i>Frontiers in Oncology</i>. Keywords co-occurrence analysis can be roughly summarized into four clusters: Risk prediction, diagnosis, treatment and prognosis of liver diseases. \"Machine learning\", \"deep learning\", \"convolutional neural network\", \"CT\", and \"microvascular infiltration\" have been popular research topics in recent years.</p><p><strong>Conclusion: </strong>AI is widely applied in the risk assessment, diagnosis, treatment, and prognosis of liver diseases, with a shift from invasive to noninvasive treatment approaches.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"101721"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen.","authors":"Vanessa Pamela Salolin Vargas, Marisa Gasbarra, Ernesto Calderon-Martinez, Yash R Shah, Dushyant Singh Dahiya, Mauricio Garcia Saenz de Sicilia","doi":"10.4254/wjh.v17.i3.105255","DOIUrl":"10.4254/wjh.v17.i3.105255","url":null,"abstract":"<p><p>In this editorial, we comment on the article by Zhao <i>et al</i> which highlighted how patients having nonalcoholic fatty liver disease (NAFLD) were more susceptible to drug-induced lung injury (DILI). This article looked at the downstream effects of metabolic profiles and biochemical processes after medication and substance use. Although previous studies looked at how NAFLD and DILI were related, there is a lack of information on the consequences of everyday medication and substance use. NAFLD is one of the most common chronic liver diseases worldwide and it has been found to be closely related to metabolic syndrome and cardiovascular disease. The aim of this editorial is to analyze the interaction between NAFLD and DILI, what clinical manifestations can occur and what the prognosis of these patients will be.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"105255"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of bile acid signal transduction causes neurological dysfunction in cirrhosis rats.","authors":"Chao Ren, Li Cha, Shu-Yue Huang, Guo-Hui Bai, Jin-Hui Li, Xin Xiong, Yu-Xing Feng, Dui-Ping Feng, Long Gao, Jin-Yu Li","doi":"10.4254/wjh.v17.i3.101340","DOIUrl":"10.4254/wjh.v17.i3.101340","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The pathogenesis of hepatic encephalopathy (HE) remains unclear, and the classical theory of ammonia toxicity lacks sufficient justification.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To investigate the potential of bile acids as intervention targets for HE.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study employed 42 wild-type male SD rats weighing 200 ± 20 g. Using a random number table method, two rats were randomly selected to undergo common bile duct ligation (BDL). The remaining 40 rats were randomly assigned to four groups serving as controls: The vehicle + control diet (VC) group, the thioacetamide (TAA) group, the TAA + total bile acids (TAAT) group, and the TAA + cholestyramine (TAAC) group. Except for the VC group, all rats were intraperitoneally injected with 100 mg/kg TAA solution once daily for ten consecutive days to establish a HE model. Simultaneously, the TAAT and TAAC groups were administered a diet containing 0.3% bile acids (derived from BDL rats) and 2% cholestyramine, respectively, by gavage for ten days. For the BDL rat model group, the common BDL procedure was performed following the aforementioned protocol. After four weeks, laparotomy revealed swollen bile ducts at the ligation site, and bile was collected. Following successful modeling, behavioral tests, including the elevated plus maze and open field test, were conducted to assess the HE status of the rats. Peripheral blood, liver, and cerebral cortex tissue samples were collected, and the total bile acid content in the serum and cerebral cortex was measured using an enzyme cycling method. The levels of inflammatory factors in the serum and cerebral cortex were analyzed using enzyme-linked immunosorbent assay. Liver histological examination was performed using the hematoxylin-eosin double-labeling method. Reverse transcription polymerase chain reaction, western blot, immunohistochemistry, and other techniques were employed to observe the expression of microglial activation marker ionized calcium-binding adaptor molecule-1 and Takeda G protein-coupled receptor 5 (TGR5) protein.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Compared to the VC group, the TAA group exhibited an exacerbation of HE in rats. The total bile acid content, pro-inflammatory factors [interleukin-1β (IL-1β), IL-6], and the anti-inflammatory factor IL-10 in both the serum and cerebral cortex were significantly elevated. Similarly, the expression of the TGR5 receptor in the cerebral cortex was upregulated. To investigate the impact of total bile acids on HE in rats, comparisons were made with the TAA group. In the TAAT group, the severity of HE was further aggravated, accompanied by increased total bile acid content in the serum and cerebral cortex, elevated pro-inflammatory factors (IL-1β, IL-6), reduced levels of the anti-inflammatory factor IL-10, and decreased expression of the TGR5 receptor in the cerebral cortex. In the TAAC group, the severity of HE was alleviated. This group showed reductions ","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"101340"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of portal pressure gradient reduction on outcomes after transjugular intrahepatic portosystemic shunt in portal hypertension patients.","authors":"Zhi-Bin Wang, Bing Zhu, Ming-Ming Meng, Yi-Fan Wu, Yu Zhang, Dong-Ze Li, Hua Tian, Fu-Chuan Wang, Yi-Fan Lv, Qiu-Xia Ye, Fu-Quan Liu","doi":"10.4254/wjh.v17.i3.103261","DOIUrl":"10.4254/wjh.v17.i3.103261","url":null,"abstract":"<p><strong>Background: </strong>Portal hypertension (PHT), a complication of liver cirrhosis, is sometimes managed with transjugular intrahepatic portosystemic shunt (TIPS) to reduce portal pressure. Although effective, TIPS poses risks, including hepatic encephalopathy (HE). This study investigates whether a significant reduction in the portal pressure gradient (PPG) after TIPS improves outcomes in PHT patients.</p><p><strong>Aim: </strong>To evaluate the impact of post-TIPS PPG reduction on clinical outcomes and explore the relationship between PPG reduction and portal vein diameter.</p><p><strong>Methods: </strong>This retrospective cohort study included 815 patients with PHT who underwent TIPS at two tertiary hospitals between 2014 and 2022. Patients were categorized based on whether they achieved a 50% reduction in PPG. Propensity score matching was applied to balance baseline characteristics. Kaplan-Meier analysis assessed clinical outcomes, including rebleeding, HE, liver failure, and hepatocellular carcinoma. Cox regression identified risk factors, and Spearman correlation analyzed the relationship between PPG reduction and portal vein diameter.</p><p><strong>Results: </strong>Patients with a PPG reduction > 50% had significantly lower risks of rebleeding (<i>P</i> = 0.004), shunt dysfunction (<i>P</i> = 0.002), and mortality (<i>P</i> = 0.024) compared to those with a PPG reduction ≤ 50%. However, these patients faced higher risks of HE (<i>P</i> < 0.001) and liver failure (<i>P</i> = 0.003). A significant negative correlation was observed between the percentage of PPG reduction and portal vein diameter (ρ = -0.632, <i>P</i> < 0.001), suggesting that patients with smaller portal vein diameters may achieve greater PPG reductions.</p><p><strong>Conclusion: </strong>A significant PPG reduction following TIPS is associated with improved clinical outcomes, including reduced risks of rebleeding, shunt dysfunction, hepatocellular carcinoma, and mortality, though it increases HE and liver failure risks. The observed correlation between portal vein diameter and PPG reduction highlights the potential role of portal vein anatomy in predicting TIPS efficacy, warranting further investigation.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"103261"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of dietary supplement use among United States patients with steatotic liver disease: Vitamins, minerals and botanicals.","authors":"Melinda Wang, Gabrielle Jutras, Giuseppe Cullaro, Anand Dhruva, Jennifer C Lai","doi":"10.4254/wjh.v17.i3.103537","DOIUrl":"10.4254/wjh.v17.i3.103537","url":null,"abstract":"<p><strong>Background: </strong>Dietary supplement (DS) usage among United States adults has significantly increased. Patients with steatotic liver disease (SLD) may have unique motivations to take DS in light of their liver condition and co-morbidities.</p><p><strong>Aim: </strong>To characterize DS use in SLD patients and explore motivations for their use.</p><p><strong>Methods: </strong>Adults ≥ 18 years old with complete transient elastography and dietary data from the National Health and Nutrition Examination Survey between January 2017 and March 2020 were studied. SLD was defined using consensus criteria, combining clinical indicators with elastography thresholds. The DS Questionnaire (DSQ) was used to record participants' use of DSQ. Sample weights were applied to estimate national prevalence.</p><p><strong>Results: </strong>Of 2413 participants with SLD, 1058 reported using DS, for an estimated prevalence of 44.8% [standard error (SE) 2.4] with an average of 2.6 (SE 0.2) DS per person. Among SLD participants taking DSQ, 53.2% (SE 3.3) reported using non-vitamin/non-mineral ones, with an average of 1.8 (SE 0.1) such supplements per person. DS users were more likely to be female, have higher levels of education, and have greater food security (P < 0.02 for all). The most common motivations for using DS were to follow doctor's advice (36.7%, SE 1.8), to improve overall health (22.1%, SE 2.0), and to maintain health (19.2%, SE 1.9).</p><p><strong>Conclusion: </strong>Nearly half of individuals with SLD report taking DS. This study underscores the pressing need to deepen our understanding of DS use/motivations to develop tailored patient counseling strategies.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"103537"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of research on glucose transporter proteins in hepatocellular carcinoma.","authors":"Zheng Ruan, Yan Wang, Lei Shi, Xiao-Jun Yang","doi":"10.4254/wjh.v17.i3.104715","DOIUrl":"10.4254/wjh.v17.i3.104715","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a malignant tumour with high prevalence and mortality rate worldwide. Metabolic reprogramming of cancer cells may be a major factor in the process of this disease. Glucose transporter proteins (GLUTs) are members of the major facilitator superfamily of membrane transporters, playing a pivotal role in the metabolic reprogramming and tumour progression in HCC. This review discusses the advances in the study of GLUTs in HCC, including the expression patterns, functions and possibilities of GLUTs. In HCC, the expression levels of GLUTs are closely associated with tumour aggressiveness, metabolic reprogramming and prognosis. A series of inhibitors have been demonstrated efficacy in inhibiting HCC cell growth and glucose uptake in <i>in vitro</i> and <i>in vivo</i> models. These inhibitors offer a novel approach to HCC treatment by reducing the glucose metabolism of tumour cells, thereby impeding tumour growth, and concurrently enhancing the sensitivity to chemotherapeutic agents. This reminds us of the urgent need to elucidate GLUTs' roles in HCC and to determine the most effective ways to translate these findings into clinical practice.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"104715"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establish and validate an artificial neural networks model used for predicting portal vein thrombosis risk in hepatitis B-related cirrhosis patients.","authors":"Pei-Pei Meng, Fei-Xiang Xiong, Jia-Liang Chen, Yang Zhou, Xiao-Li Liu, Xiao-Min Ji, Yu-Yong Jiang, Yi-Xin Hou","doi":"10.4254/wjh.v17.i3.97767","DOIUrl":"10.4254/wjh.v17.i3.97767","url":null,"abstract":"<p><strong>Background: </strong>The portal vein thrombosis (PVT) can exacerbate portal hypertension and lead to complications, increasing the risk of mortality.</p><p><strong>Aim: </strong>To evaluate the predictive capacity of artificial neural networks (ANNs) in quantifying the likelihood of developing PVT in individuals afflicted with hepatitis B-induced cirrhosis.</p><p><strong>Methods: </strong>A retrospective study was conducted at Beijing Ditan Hospital, affiliated with Capital Medical University, including 986 hospitalized patients. Patients admitted between January 2011 and December 2014 were assigned to the training set (685 cases), while those hospitalized from January 2015 to December 2016 were divided into the validation cohort (301 cases). Independent risk factors for PVT were identified using COX univariate analysis and used to construct an ANN model. Model performance was evaluated through metrics such as the area under the receiver operating characteristic curve (AUC) and concordance index.</p><p><strong>Results: </strong>In the training set, PVT occurred in 19.0% of patients within three years and 23.7% within five years. In the validation cohort, PVT developed in 16.7% of patients within three years and 24.0% within five years. The ANN model incorporated nine independent risk factors: Age, ascites, hepatic encephalopathy, gastrointestinal varices with bleeding, Child-Pugh classification, alanine aminotransferase levels, albumin levels, neutrophil-to-lymphocyte ratio, and platelet. The model achieved an AUC of 0.967 (95%CI: 0.960-0.974) at three years and 0.975 (95%CI: 0.955-0.992) at five years, significantly outperforming existing models such as model for end-stage liver disease and Child-Pugh-Turcotte (all <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The ANN model demonstrated effective stratification of patients into high- and low-risk groups for PVT development over three and five years. Validation in an independent cohort confirmed the model's predictive accuracy.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 3","pages":"97767"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis.","authors":"Xue-Cheng Tong, Kai Liu, Ze-Yu Huang, Xiu-Jun Zhang, Yuan Xue","doi":"10.4254/wjh.v17.i2.99092","DOIUrl":"https://doi.org/10.4254/wjh.v17.i2.99092","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) surveillance is crucial for patients with compensated cirrhosis (CC) and decompensated cirrhosis (DC). Increasing evidence has revealed a connection between thyroid hormone (TH) and HCC, although this relationship remains contentious. Complements and immunoglobulin (Ig), which serve as surrogates of cirrhosis-associated immune dysfunction, are associated with the severity and outcomes of liver cirrhosis (LC). To date, there is a lack of evidence supporting the recommendation of TH, Ig, and complement tests in patients at high risk of HCC.</p><p><strong>Aim: </strong>To assess the predictive value of TH, Ig, and complements for HCC development.</p><p><strong>Methods: </strong>Data from 142 patients, comprising 72 patients with CC and 70 patients with DC, were analysed as a training set. Among them, 100 patients who underwent complement and Ig tests were considered for internal validation. Logistic regression was employed to identify independent risk factors for HCC development.</p><p><strong>Results: </strong>The median follow-up duration was 32 (24-37 months) months. The incidence of HCC was significantly higher in the DC group (16/70, 22.9%) compared to the CC group (3/72, 4.2%) (<i>χ</i>² = 10.698, <i>P</i> < 0.01). Patients with DC exhibited lower total tetraiodothyronine (TT4), total triiodothyronine (TT3), free triiodothyronine, complement C3, and C4 (all <i>P</i> < 0.01), and higher IgA and IgG (both <i>P</i> < 0.01). In both CC and DC patients, TT3 and TT4 positively correlated with alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transpeptidase (GGT). IgG positively correlated with IgM, IgA, ALT, and AST, while it negatively correlated with C3 and C4. Multivariable analysis indicated that age, DC status, and GGT were independent risk factors for HCC development.</p><p><strong>Conclusion: </strong>The predictive value of TH, Ig, and complements for HCC development is suboptimal. Age, DC, and GGT emerge as more significant factors during HCC surveillance in hepatitis B virus-related LC.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 2","pages":"99092"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease.","authors":"Li-Hui Zhang, Su-Tong Liu, Qing Zhao, Xiao-Yan Liu, Tong Liu, Qiang Zhang, Ming-Hao Liu, Wen-Xia Zhao","doi":"10.4254/wjh.v17.i2.102328","DOIUrl":"https://doi.org/10.4254/wjh.v17.i2.102328","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is a progressive disease. Without effective interventions, NAFLD can gradually develop to non-alcoholic steatohepatitis, fatty liver fibrosis, liver cirrhosis and even hepatocellular carcinoma. It is still to investigate the precise molecular mechanism behind the pathophysiology of NAFLD. Triggering receptor expressed on myeloid cells 2 (TREM2) can sense tissue injury and mediate immune remodeling, thereby inducing phagocytosis, lipid metabolism, and metabolic transfer, promoting cell survival and combating inflammatory activation. NAFLD might develop as a result of TREM2's regulatory role. We here briefly summarize the biological characteristics of TREM2 and its functions in the disease progression of NAFLD. Moreover, we propose to broaden the therapeutic strategy for NAFLD by targeting TREM2.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 2","pages":"102328"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}